Once-daily atomoxetine for treating pediatric attention-deficit/ hyperactivity disorder: Comparison of morning and evening dosing

Clinical Pediatrics

Volumn 48, Issue 7, 2009, Pages 723-733

  Block, Stan L ^a   Kelsey, Douglas ^b   Coury, Daniel ^c   Lewis, Donald ^d   Quintana, Humberto ^e   Sutton, Virginia ^f   Schuh, Kory ^b   Allen, Albert J ^f   Sumner, Calvin ^f  

^a Kentucky Pediatric Research Institute   (United States)

^b Lilly USA   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d Monarch Research Associates   (United States)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; Atomoxetine; Child; Duration of effect; Once daily

Indexed keywords

ATOMOXETINE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD BEHAVIOR; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; PATIENT COMPLIANCE; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SOMNOLENCE; STOMACH DISCOMFORT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROPYLAMINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 68949151924     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922809335321     Document Type: Article

References (12)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
2. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114:e1-e8.
3. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
4. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:e83.
5. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63:1140-1147.
6. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
7. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford Press; 1998.
8. Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord. 2001;5:39-47.
9. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: US Department of Health, Education and Welfare; 1976.
10. Conners CK Conners' Rating Scales-Revised. Toronto, Ontario, Canada: Multi-Health Systems; 1997.
11. Sutton V, Sumner C, Allen AJ, Feng W, Schuh K, Michelson D. Validity, reliability, and responsiveness of the DPREMB-R scale for ADHD. Paper presented at: Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 14-19, 2003; Miami, FL.
12. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.12. 4 th ed. Cary, NC: SAS Institute; 1997.